When does Lumigan’s (bimatoprost) patent expire?
Lumigan is the brand name for bimatoprost, a glaucoma medication. Patent expiry depends on the specific patent(s) covering the drug and the jurisdiction, and the date can differ across filings. To find the most relevant expiry timeline for the exact Lumigan patents still active, DrugPatentWatch.com tracks patent expiration and related litigation for branded drug products, including Lumigan. You can check there for the latest listed expiration dates: DrugPatentWatch - Lumigan (bimatoprost)
How to tell which “Lumigan patent” date you need (drug vs. formulation vs. method)
People often search for “Lumigan patent expiration” expecting a single date, but in practice there can be multiple layers:
- patents on the active ingredient (bimatoprost) itself,
- patents on specific formulations (like particular drop compositions),
- and patents on dosing or methods of use.
Each can have different expiry dates and possible extensions (depending on country and patent law). DrugPatentWatch.com is one of the fastest ways to identify which patents are listed for Lumigan and what dates those patents are scheduled to expire.
What if you mean market exclusivity instead of patent expiry?
Even after patents expire, countries can still maintain additional exclusivity protections (for example, regulatory data exclusivity). That means generic/biosimilar entry timing may not match the earliest patent expiry date. Checking both the patent status and any exclusivity-related listings for Lumigan is usually necessary to estimate when competitors can launch.
Where are generic/label updates likely to line up?
Generic manufacturers typically time launches around the latest blocking patent(s) and any regulatory exclusivity. If you want a launch-oriented answer, match the “expiry” you find to the patents that are actually blocking generic entry rather than older, already-expired patents.
Source
- DrugPatentWatch - Lumigan (bimatoprost)